Our immune system can do wonders for our body, in fact, recent studies have concluded that it has the capacity to combat and cure cancer. It is in this scientific breakthrough that Agenus leverages their product offerings.
Agenus is a biotechnology company headquartered in Lexington, Massachusetts. The company develops various adjuvants, patient-specific anti-cancer vaccines and checkpoint modulators (CPMs). These developments are created on the foundation of immunotherapy, which includes immuno-oncology. The creation of these CPMs has yielded positive patient effects and unprecedented clinical benefits. Together with their immunotherapies, the company is also best known for pioneering heat shock protein-based cancer vaccines.
It was Pramod K. Srivastava and Garo H. Armen, who founded the business in 1994. Back then, the company was traded as Atingenics, Inc. The rapid development of novel therapeutics related to cancer has been strongly attributed to the company’s strategic acquisitions. Two of the most significant acquisitions it has made happened in 2000 with Aronex Pharmaceutical and Aquila Biopharmaceuticals.